Please login to the form below

Not currently logged in
Email:
Password:

Former Pfizer R&D head LaMattina to advise Ziarco

He previously spent 30 years at US pharma firm

Dr John LaMattina ZiarcoUK-based biotech Ziarco has hired former head of R&D at Pfizer, Dr John LaMattina, as a strategic R&D adviser.

Dr LaMattina spent 30 years at Pfizer in total, including four years as president of global research and development from 2003 until his retirement from the US pharma giant in 2007.

Earlier roles he held at Pfizer included senior VP of worldwide development and chief medical officer.

In his new role, he will help Ziarco to advance its development strategies for its investigational compounds to tackle inflammatory and allergic diseases.

These include a H4 agonist that has just completed a phase I study.

In addition to his role at Ziarco, LaMattina is a senior partner at PureTech Venues and serves on the board of directors at Ligand Pharmaceuticals and the scientific advisory board of Trevena Pharmaceuticals.

20th March 2013

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Oncosec

OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...

Latest intelligence

Kulveer Singh
Surviving cancer: a new era for patients
Now more than ever, a shift in perspective is needed...
Crisis? No problem!
Issues planning & management for pharma spokespeople, by Andrew Smith...
Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....

Infographics